Knezevic Nebojsa Nick, Aijaz Tabish, Candido Kenneth D, Kovaleva Svetlana, Lissounov Alexei, Knezevic Ivana
Department of Anesthesiology, Advocate Illinois Masonic Medical Center, Chicago, IL, United States.
Department of Anesthesiology, The University of Illinois at Chicago, Chicago, IL, United States.
Front Pharmacol. 2019 May 15;10:504. doi: 10.3389/fphar.2019.00504. eCollection 2019.
To compare gabapentin extended-release, a gastro-retentive formulation, in relieving postamputation pain among gabapentin-experienced and gabapentin-naïve patients.
Open-labeled pilot study.
Sixteen patients with postamputation pain (8 patients in the gabapentin-experienced and 8 patients in the gabapentin-naïve groups).
Patients were started on gabapentin extended-release and were followed up for 8 weeks. Patients reported their pain severity during rest and movement using a numeric rating scale (NRS), interference of pain with daily activities using the modified brief pain inventory (MBPI) questionnaire, and treatment satisfaction using the treatment satisfaction questionnaire for medication (TSQM).
Patients from both gabapentin-experienced and gabapentin-naïve groups achieved a significant and sustainable pain relief over the course of therapy. The pain scores at rest decreased in both gabapentin-experienced and gabapentin-naïve groups from 5.88 ± 1.36 and 4.88 ± 2.95 to 1.88 ± 0.99 and 1.38 ± 1.51, respectively. An average percent of pain relief with gabapentin extended-release was noted to be significant ( < 0.01) after 8 weeks of therapy among gabapentin-experienced (81.25 ± 16.42%) and gabapentin-naïve groups (85 ± 17.73%) when compared to baseline for gabapentin-experienced (31.25 ± 29%) and gabapentin-naïve groups (36.25 ± 34.2%), respectively. Gabapentin-experienced and gabapentin-naïve groups had no significant difference in global satisfaction from treatment (79.14 ± 10.47 and 83.3 ± 20.82), convenience of treatment (73.78 ± 19.04 and 90.44 ± 11.66), effectiveness of treatment (72.6 ± 10.1 and 79.73 ± 11.6). The only statistically significant difference among gabapentin-experienced and gabapentin-naïve groups was found in adverse event tolerability (65.78 ± 10.36 and 85.8 ± 10.14, < 0.01).
Once-daily dosing of gabapentin-extended release showed significant improvement in pain severity and functional status, with no difference found between gabapentin-experienced versus gabapentin-naïve patients.
比较加巴喷丁缓释剂（一种胃滞留制剂）在有使用加巴喷丁经验的患者和未使用过加巴喷丁的患者中缓解截肢后疼痛的效果。
开放标签的试点研究。
16例截肢后疼痛患者（有使用加巴喷丁经验的患者8例，未使用过加巴喷丁的患者8例）。
患者开始服用加巴喷丁缓释剂，并随访8周。患者使用数字评分量表（NRS）报告休息和活动时的疼痛严重程度，使用改良简明疼痛问卷（MBPI）报告疼痛对日常活动的干扰，并使用药物治疗满意度问卷（TSQM）报告治疗满意度。
有使用加巴喷丁经验的患者组和未使用过加巴喷丁的患者组在治疗过程中均实现了显著且持续的疼痛缓解。有使用加巴喷丁经验的患者组和未使用过加巴喷丁的患者组休息时的疼痛评分分别从5.88±1.36和4.88±2.95降至1.88±0.99和1.38±1.51。与基线相比，有使用加巴喷丁经验的患者组（31.25±29%）和未使用过加巴喷丁的患者组（36.25±34.2%）在接受加巴喷丁缓释剂治疗8周后，平均疼痛缓解百分比显著（<0.01），分别为81.25±16.42%和85±17.73%。有使用加巴喷丁经验的患者组和未使用过加巴喷丁的患者组在总体治疗满意度（79.14±10.47和83.3±20.82）、治疗便利性（73.78±19.04和90.44±11.66）、治疗有效性（72.6±10.1和79.73±11.6）方面无显著差异。有使用加巴喷丁经验的患者组和未使用过加巴喷丁的患者组之间唯一具有统计学意义的差异在于不良事件耐受性（65.78±10.36和85.8±10.14，<0.01）。
每日一次服用加巴喷丁缓释剂在疼痛严重程度和功能状态方面有显著改善，有使用加巴喷丁经验的患者与未使用过加巴喷丁的患者之间无差异。
